XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 30.89 | 0.01 | -0.30 |
| FCF Yield | -12.24% | -12.85% | -13.66% | -7.12% |
| EV / EBITDA | -14.44 | -5.37 | -5.12 | -11.42 |
| Quality | ||||
| ROIC | -29.75% | -34.46% | -22.01% | -16.14% |
| Gross Margin | 0.67% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.58 | 0.40 | 0.67 | -2.41 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -136.49% | 21.53% | 14.11% | -23.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 1.83 | 2.38 | 2.88 |
| Interest Coverage | -25.26 | -191.30 | -80.01 | -49.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -79.57 | 0.00 | -730.00 | -730.00 |